Should Patients with Lower Extremity PAD Be Referred to Cardiology?
Yes, patients with lower extremity peripheral artery disease should be referred to cardiology for comprehensive cardiovascular risk assessment and optimization of medical therapy, as PAD is fundamentally a cardiovascular disease with high rates of concomitant coronary artery disease and increased risk of myocardial infarction, stroke, and death.
Rationale for Cardiology Referral
PAD as a Cardiovascular Disease
PAD is not merely a limb circulation problem—it represents systemic atherosclerosis with profound cardiovascular implications. The 2024 ACC/AHA guidelines explicitly state that PAD is "a common cardiovascular disease associated with increased risk of amputation, myocardial infarction, stroke, and death" 1. This fundamental understanding should drive referral patterns.
High Prevalence of Concomitant Coronary Disease
The evidence for concurrent coronary artery disease (CAD) in PAD patients is striking:
- Over 50% of asymptomatic PAD patients have significant CAD on coronary angiography, with 29% having single-vessel disease, 14% two-vessel disease, and 10% three-vessel disease 2
- Importantly, 72% of PAD patients with CAD have multi-vessel disease, yet only 13% report angina symptoms 3
- The 2024 ESC guidelines note that 5-9% of CAD patients have concomitant carotid stenosis >70%, highlighting the interconnected nature of vascular disease 4
Cardiology's Role in Optimizing Medical Therapy
Cardiology referral is essential because comprehensive cardiovascular risk reduction requires aggressive medical management that cardiologists are specifically trained to implement 1, 4. This includes:
- High-intensity statin therapy (Class I recommendation) to reduce both cardiovascular events and improve walking distance 1
- Dual pathway inhibition with rivaroxaban 2.5 mg twice daily plus aspirin 81 mg daily for patients not at increased bleeding risk—this combination prevents major adverse cardiovascular events AND major adverse limb events 1
- Antihypertensive optimization as part of comprehensive cardiovascular risk management 1
- Diabetes management with consideration of SGLT-2 inhibitors and GLP-1 receptor agonists, which have shown benefits for cardiovascular and limb outcomes 5
When Cardiology Evaluation is Most Critical
The 2024 ESC guidelines provide specific scenarios where cardiology assessment is particularly important 4:
- Before lower-limb revascularization procedures in patients with poor functional capacity or significant risk factors
- Patients with diabetes, multiple cardiovascular risk factors, or multi-level PAD (both proximal and distal disease)—these patients have 2.5 times higher odds of multi-vessel CAD 3
- All symptomatic PAD patients where CAD screening "may be helpful to optimize medical treatment" 4
The Multispecialty Care Team Model
Both 2024 guidelines emphasize that optimal PAD care requires a multispecialty team approach 1, 4. Cardiology is a core member of this team, not an optional consultant. The team should include:
- Cardiology for cardiovascular risk assessment and medical optimization
- Vascular surgery/interventional specialists for revascularization decisions
- Podiatry for foot care across all PAD subsets 1
- Primary care for coordination and long-term management
Common Pitfalls to Avoid
The biggest mistake is assuming that absence of cardiac symptoms means absence of significant CAD. Recent research demonstrates that myocardial perfusion abnormalities drive much of the MACE risk in PAD patients 6, yet most patients with severe CAD remain asymptomatic 3.
Another critical error is treating PAD as solely a limb problem rather than recognizing it as a marker of systemic atherosclerosis requiring comprehensive cardiovascular management 1.
Practical Implementation
For every PAD patient diagnosed (whether asymptomatic, claudication, or chronic limb-threatening ischemia):
- Refer to cardiology for cardiovascular risk stratification and medical therapy optimization
- Initiate high-intensity statin immediately while awaiting cardiology evaluation 1
- Consider stress testing or coronary CT angiography in cardiology consultation, particularly for patients with diabetes, multiple risk factors, or planned revascularization 4, 2
- Ensure antiplatelet/antithrombotic therapy is optimized—consider dual pathway inhibition (rivaroxaban + aspirin) if bleeding risk is acceptable 1
The evidence strongly supports that cardiology involvement improves both cardiovascular and limb outcomes through comprehensive medical management that extends well beyond what is typically provided in non-cardiology settings 5.